Drug
Eflornithine clinical trials
Also written DFMO, Vaniqa, MDL 71782 and RMI 71782.
- studies test it
- 42
- open now
- 6
- in phase 3
- 8
- first study started
- 1995
Keep track of what changes. Save the Eflornithine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1998 | 3 |
| 1999 | 1 |
| 2001 | 3 |
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 6 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 10
- Phase 2
- 26
- Phase 3
- 8
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 34
Giselle Sholler (6) · National Cancer Institute (NCI) (4) · Cancer Prevention Pharmaceuticals, Inc. (3) · National Skin Centre (2) · University of Alabama at Birmingham (2) · Aminex Therapeutics, Inc. (2) · University of Wisconsin, Madison (2) · University of Arizona (2)
Often tested with
Tested in the same studies.
Sulindac (5) · Diclofenac (2) · Diclofenac Sodium Gel (2) · AMXT-1501 (2) · Tretinoin (1) · Hydroquinone (1) · Celecoxib (1) · Cyclophosphamide (1)
Studies
Open first, then newest update. How each study uses Eflornithine is read from its arms, and is right about nine times in ten.
Testing it · 42
- DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed MedulloblastomaRecruitingPhase 2Giselle ShollerNCT04696029Written as Difluoromethylornithine
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade GliomasRecruitingPhase 1/2Mayo ClinicNCT07468136Written as Eflornithine
- DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaRecruitingPhase 1/2Montefiore Medical CenterNCT06892678Written as DFMO
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06059118Written as DFMO
- Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade GliomaRecruitingEarly Phase 1Mayo ClinicNCT05717153Written as Eflornithine
- Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaRecruitingPhase 1Orbus Therapeutics, Inc.NCT05879367Written as Eflornithine (Dose Level 1)
- S0820, Adenoma and Second Primary Prevention TrialActive, not recruitingPhase 3SWOG Cancer Research NetworkNCT01349881Written as Eflornithine plus sulindac
- Randomized Split-Face Controlled Study to Evaluate the Effectiveness of Topical Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% as Compared to Topical Tretinoin 0.05% + Hydroquinone 4% + Fluocinolone 0.01% for the Treatment of MelasmaCompletedPhase 2National Skin CentreNCT07876323Written as Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% cream
- Neuroblastoma Maintenance Therapy TrialActive, not recruitingPhase 2Giselle ShollerNCT02679144Written as Difluoromethylornithine (DFMO)
- Eflornithine (DFMO) and Etoposide for Relapsed/Refractory NeuroblastomaActive, not recruitingPhase 2Giselle ShollerNCT04301843Written as Eflornithine
- Chemoprevention of Gastric CarcinogenesisCompletedPhase 2Vanderbilt-Ingram Cancer CenterNCT02794428Written as Eflornithine
- TArgeting Type 1 Diabetes Using POLyamines (TADPOL)Active, not recruitingPhase 2Emily K. SimsNCT05594563Written as DFMO
- Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)SuspendedPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT06219174Written as Difluoromethylornithine
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaActive, not recruitingPhase 2Children's Oncology GroupNCT03794349Written as Eflornithine Hydrochloride
- Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin CancerCompletedPhase 2University of Alabama at BirminghamNCT04091022Written as Solaraze and Vaniqa
- Efficacy of Eflornithine Hydrochloride Cream in the Treatment of Melasma: A Randomized, Double-blinded, Split-face Controlled StudyCompletedPhase 2National Skin CentreNCT06957834Written as Eflornithine hydrochloride cream
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/TopotecanCompletedPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT02030964Written as DFMO
- Oral AMXT 1501 Dicaprate in Combination With IV DFMOTerminatedPhase 1/2Aminex Therapeutics, Inc.NCT05500508Written as DFMO
- Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in RemissionCompletedPhase 2Giselle ShollerNCT02395666Written as DFMO
- Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With EtoposideCompletedPhase 1Giselle ShollerNCT01059071Written as DFMO
See all 42 studies that test Eflornithine →
Given in every arm · 3 — Eflornithine is usual care beside what is tested
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruitingPhase 1/2Aminex Therapeutics, Inc.NCT07287917Written as DFMO
- Eflornithine (DFMO) for Ewing Sarcoma and OsteosarcomaRecruitingPhase 2Milton S. Hershey Medical CenterNCT07321912Written as Eflornithine
- Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasRecruitingPhase 1/2Milton S. Hershey Medical CenterNCT06465199Written as Eflornithine (DFMO)
As the comparator · 2 — what is tested is compared with Eflornithine
Codes
What other systems call Eflornithine · ClinicalTrials.gg INT006930
- MeSH (NLM) D000518EflornithineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ZQN1G5V6SREFLORNITHINEConfirmed FDA, NLM, Wikidata
- RxNorm 569Confirmed FDA, Wikidata
- Wikidata Q424751(RS)-eflornithineConfirmed FDA, NLM, Wikidata
- Wikidata Q72470623EflornithineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C226EflornithineOne source FDA
- DrugBank DB06243One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000518 | Eflornithine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ZQN1G5V6SR | EFLORNITHINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 569 | — | Confirmed FDA, Wikidata |
| Wikidata | Q424751 | (RS)-eflornithine | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q72470623 | Eflornithine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C226 | Eflornithine | One source FDA |
| DrugBank | DB06243 | — | One source Wikidata |
Also registered as eflornithine hydrochloride (UNII 4NH22NDW9H · RxNorm 81945).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.